Premium
Incretins: B eyond type 2 diabetes
Author(s) -
Dandona Paresh,
Ghanim Husam,
Chaudhuri Ajay
Publication year - 2018
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1111/dom.13153
Subject(s) - type 2 diabetes , incretin , diabetes mellitus , medicine , receptor , pharmacology , bioinformatics , endocrinology , biology
While the use of incretins, including GLP‐1 receptor agonists and PDD‐IV inhibitors, is well established in the treatment of type 2 diabetes, many other aspects of these agents are yet to be discovered and utilized for their potential clinical benefit. These include the potential role of GLP‐1 receptor agonists in the induction of weight loss, blood pressure reduction, anti‐inflammatory and nephro‐ and cardio‐protective actions. Their potential benefit in type 1 diabetes is also being investigated. This review will attempt to comprehensively describe novel discoveries in the field of incretin pathophysiology and pharmacology beyond their classical role in the treatment of type 2 diabetes.